Advanced lung cancer inflammation index (ALI) as a prognostic marker for locally advanced and metastatic cancer: A prospective study. Phase II study of disitamab vedotin (RC48) in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results